Advertisement

National Academy Science Letters

, Volume 37, Issue 1, pp 45–50 | Cite as

Mechanistic Evidence to Support the Anti-hepatitis B Viral Activity of Multifunctional Scaffold & Conformationally Restricted Magnolol

  • Rajeev K. SinglaEmail author
Research Article

Abstract

Magnolol, phenolic bioactive phytomolecule, is a potential antihepatitis B viral agent. Current study is to mechanistically analyze the probable site of action for magnolol. Magnolol has been docked with EF3-CaM adenylyl cyclase (1PK0), deoxycytidine kinase (2NOA), human nucleoside diphosphate kinase (3FKB), human hepatitis B viral capsid (1QGT), hepatitis B X-interacting protein (3MSH) proteins using GRIP docking methodology, and compared with reference ligands like adefovir diphosphate (active metabolite of adefovir), lamivudine, tenofovir monophosphate (active metabolite of tenofovir) and tenofovir diphosphate (active metabolite of tenofovir). Results revealed its preferential interactability towards 2NOA i.e. deoxycytidine kinase, which raise up its chance to get metabolized into phosphorylated analogs, providing further impetus for discovery and clinical development of semi-synthetic analogs of magnolol. Out of all the virtually designed magnolol derivatives, Leadgrow_ML1449 have superior binding affinities towards all the test proteins except EF3-CaM adenylyl cyclase.

Keywords

Magnolol Antihepatitis B viral activity Docking studies GRIP docking Natural antiviral agent 

Notes

Acknowledgments

GRIP docking was performed using VLife MDS 4.3 software funded by Science & Engineering Research Board (Department of Science & Technology), Govt. of India. Author Rajeev K. Singla is receiving PI/SERB’s Young Scientist’s Fellowship from SERB (Department of Science & Technology), Govt. of India.

References

  1. 1.
    Attrey DP, Singh AK, Katyal J et al (2012) Pharmacognostical characterization & preliminary phytochemical investigation of seabuckthorn (Hippophae rhamnoides L.) leaves. Indo Global J Pharm Sci 2(2):108–113Google Scholar
  2. 2.
    Antonelli G, Turriziani O (2012) Antiviral therapy: old and current issues. Int J Antimicrob Agents 40:95–102CrossRefGoogle Scholar
  3. 3.
    Elion GB, Furman PA, Fyfe JA et al (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74:5716–5720CrossRefGoogle Scholar
  4. 4.
    Fyfe JA, Keller PM, Furman PA et al (1978) Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl) guanine. J Biol Chem 253:8721–8727Google Scholar
  5. 5.
    Talwar GP, Dar SA, Rai MK et al (2008) A novel polyherbal microbiocide with inhibitory effect on bacterial, fungal and viral genital pathogens. Int J Antimicrob Agents 32:180–185CrossRefGoogle Scholar
  6. 6.
    Li J, Huang Y, Guan XL et al (2012) Anti-hepatitis B virus constituents from the stem bark of Streblus asper. Phytochemistry 82:100–109CrossRefGoogle Scholar
  7. 7.
    Castilla V, Barquero AA, Mersich SE et al (1998) In vitro anti-Junin virus activity of a peptide isolated from Melia azedarach L. leaves. Int J Antimicrob Agents 10:67–75CrossRefGoogle Scholar
  8. 8.
    Chen YH, Huang PH, Lin FY et al (2011) Magnolol: a multifunction compound isolated from the Chinese medicinal plant Magnolia officinalis. Eur J Integr Med 3:e317–e324CrossRefGoogle Scholar
  9. 9.
    Shen Y, Zhukovskaya NL, Zimmer MI et al (2004) Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci USA 101:3242–3247CrossRefGoogle Scholar
  10. 10.
    Sabini E, Hazra S, Konrad M et al (2007) Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase. Nucleic Acids Res 35:186–192CrossRefGoogle Scholar
  11. 11.
    Koch K, Chen YX, Feng JY et al (2009) Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives. Nucleosides, Nucleotides Nucleic Acids 28:776–792CrossRefGoogle Scholar
  12. 12.
    Wynne SA, Crowther RA, Leslie AG (1999) The crystal structure of the human hepatitis B virus capsid. Mol Cell 3:771–780CrossRefGoogle Scholar
  13. 13.
    Garcia-Saez I, Lacroix FB, Blot D et al (2011) Structural characterization of HBXIP: the protein that interacts with the anti-apoptotic protein survivin and the oncogenic viral protein HBx. Mol Biol 405:331–340CrossRefGoogle Scholar
  14. 14.
    Singla RK, Bhat VG (2010) QSAR model for predicting the fungicidal action of 1,2,4-triazole derivatives against Candida albicans. J Enzyme Inhib Med Chem 25(5):696–701CrossRefGoogle Scholar
  15. 15.
    Malleshappa NN, Patel HM (2011) A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: a rationale approach to anticancer drug design. J Saudi Chem Soc. doi: 10.1016/j.jscs.2011.04.017 Google Scholar
  16. 16.
    Bhuva HA, Kini SG (2010) Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitor. J Mol Graph Model 29:32–37CrossRefGoogle Scholar
  17. 17.
    VLifeMDS: Molecular Design Suite (2010) VLife Sciences Technologies Pvt. Ltd., Pune, India. (www.vlifesciences.com)
  18. 18.
    Hazra S, Szewczak A, Ort S et al (2011) Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release. Biochemistry 50(14):2870–2880CrossRefGoogle Scholar

Copyright information

© The National Academy of Sciences, India 2014

Authors and Affiliations

  1. 1.Division of BiotechnologyNetaji Subhas Institute of TechnologyDwarka, New DelhiIndia

Personalised recommendations